Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice

Pharmacology

Volumn 89, Issue 3-4, 2012, Pages 149-155

  Schicho, Rudolf ^a   Storr, Martin ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cannabinoids; Experimental colitis; Inflammatory bowel disease

Indexed keywords

CANNABIDIOL; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC THERAPY; TOPICAL TREATMENT;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CANNABIDIOL; COLITIS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; MALE; MICE; PEROXIDASE; TRINITROBENZENESULFONIC ACID;

EID: 84857931127     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000336871     Document Type: Article

References (30)

1. Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517. (Pubitemid 38649869)
2. Engel MA, Neurath MF: New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010; 45: 571-583.
3. Danese S, Fiorino G, Reinisch W: Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- therapy. Aliment Pharmacol Ther 2011; 34: 1-10.
4. Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H: Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23: 891-896.
5. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-1209. (Pubitemid 38544105)
6. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA: Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 2009; 15: 1678-1685.
7. Izzo AA, Camilleri M: Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 2009; 60: 117-125.
8. Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, Guadagno F, Petrosino S, Capasso F, Di Marzo V, Izzo AA: Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl) 2009; 87: 1111-1121.
9. Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, Storr M: The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 2011; 17: 1651-1664.
10. Pertwee RG: Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005; 168: 1-51.
11. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: A metaanalysis of randomised trials. Lancet 2007; 370: 1706-1713. (Pubitemid 350100788)
12. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R: Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-527.
13. Schuelert N, McDougall JJ: The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett 2011; 500: 72-76.
14. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G: Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96: 14136-14141.
15. Pertwee RG: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: -9 -tetrahydrocannabinol, cannabidiol and -9 - tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
16. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-1101. (Pubitemid 350166046)
17. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R: Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175-185. (Pubitemid 10039764)
18. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA: Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011; 6: 237-249.
19. Huestis MA: Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005; 168: 657-690.
20. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA: Plasma cannabinoid pharmacokinetics following controlled oral delta9- tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 2011; 57: 66-75.
21. Krawisz JE, Sharon P, Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344-1350. (Pubitemid 15201434)
22. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M: The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007; 556: 75-83. (Pubitemid 46074009)
23. Sibaev A, Massa F, Yüce B, Marsicano G, Lehr HA, Lutz B, Göke B, Allescher HD, Storr M: CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. J Mol Med (Berl) 2006; 84: 513-520. (Pubitemid 43801330)
24. Kimball ES, Schneider CR, Wallace NH, Hornby PJ: Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006; 291:G364-G371. (Pubitemid 44024696)
25. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, Massa F, Buckley NE, Lutz B, Göke B, Brand S, Patel KD, Sharkey KA: Targeting endocannabinoid degradation protects against experimental colitis in mice: Involvement of CB1 and CB2 receptors. J Mol Med 2008; 86: 925-936.
26. Stintzing S, Wissniowski TT, Lohwasser C, Alinger B, Neureiter D, Ocker M: Role of cannabinoid receptors and RAGE in inflammatory bowel disease. Histol Histopathol 2011; 26: 735-745.
27. Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez De FF, Andreu M: Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 2009; 4:e6893.
28. Schicho R, Storr M: Targeting the endocannabinoid system for gastrointestinal diseases: Future therapeutic strategies. Expert Rev Clin Pharmacol 2010; 3: 193-207.
29. Schölmerich J: Review article: Systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (suppl 4):66-74. (Pubitemid 39319250)
30. Ashton CH: Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-649. (Pubitemid 29458833)